



# Effects of Medium-Chain Triglycerides on Weight Loss and Body Composition: A Meta-Analysis of Randomized Controlled Trials

CrossMark

Karen Mumme, PGDipSc; Welma Stonehouse, PhD

#### **ARTICLE INFORMATION**

Article history: Accepted 26 September 2014

#### Keywords:

Medium-chain triglycerides Body composition Obesity Blood lipids Body weight

### Supplementary materials:

PowerPoint presentation available at www.andjrnl.org

2212-2672/Copyright © 2015 by the Academy of Nutrition and Dietetics. http://dx.doi.org/10.1016/j.jand.2014.10.022

### ABSTRACT

**Background** Medium-chain triglycerides (MCTs) may result in negative energy balance and weight loss through increased energy expenditure and lipid oxidation. However, results from human intervention studies investigating the weight reducing potential of MCTs, have been mixed.

**Objective** To conduct a systematic review and meta-analysis of randomized controlled trials comparing the effects of MCTs, specifically C8:0 and C10:0, to long-chain triglycerides (LCTs) on weight loss and body composition in adults. Changes in blood lipid levels were secondary outcomes.

**Methods** Randomized controlled trials >3 weeks' duration conducted in healthy adults were identified searching Web of Knowledge, Discover, PubMed, Scopus, New Zealand Science, and Cochrane CENTRAL until March 2014 with no language restriction. Identified trials were assessed for bias. Mean differences were pooled and analyzed using inverse variance models with fixed effects. Heterogeneity between studies was calculated using  $l^2$  statistic. An  $l^2$ >50% or P<0.10 indicated heterogeneity.

**Results** Thirteen trials (n=749) were identified. Compared with LCTs, MCTs decreased body weight (-0.51 kg [95% CI-0.80 to -0.23 kg]; P<0.001;  $l^2=35\%$ ); waist circumference (-1.46 cm [95% CI -2.04 to -0.87 cm]; P<0.001;  $l^2=0\%$ ), hip circumference (-0.79 cm [95% CI -1.27 to -0.30 cm]; P=0.002;  $l^2=0\%$ ), total body fat (standard mean difference -0.39 [95% CI -0.57 to -0.22]; P<0.001;  $l^2=0\%$ ), total subcutaneous fat (standard mean difference -0.46 [95% CI -0.64 to -0.27]; P<0.001;  $l^2=20\%$ ), and visceral fat (standard mean difference -0.55 [95% CI -0.75 to -0.34]; P<0.001;  $l^2=0\%$ ). No differences were seen in blood lipid levels. Many trials lacked sufficient information for a complete quality assessment, and commercial bias was detected. Although heterogeneity was absent, study designs varied with regard to duration, dose, and control of energy intake.

**Conclusions** Replacement of LCTs with MCTs in the diet could potentially induce modest reductions in body weight and composition without adversely affecting lipid profiles. However, further research is required by independent research groups using large, well-designed studies to confirm the efficacy of MCT and to determine the dosage needed for the management of a healthy body weight and composition. J Acad Nutr Diet. 2015;115:249-263.

BESITY CONTINUES TO BE ONE OF THE BIGGEST global challenges in the 21st century, with at least 2.8 million adults dying each year from conditions resulting from being overweight or obese.<sup>1</sup> In addition, 44% of diabetes burden, 23% of ischemic heart disease burden, and between 7% and 41% of certain cancer burdens are attributable to overweight and obesity.<sup>1</sup> The rising obesity rates can be ascribed to changing dietary patterns and lifestyle

To take the Continuing Professional Education quiz for this article, log in to www.eatright.org, click the "myAcademy" link under your name at the top of the homepage, select "Journal Quiz" from the menu on your myAcademy page, click "Journal Article Quiz" on the next page, and then click the "Additional Journal CPE Articles" button to view a list of available quizzes, from which you may select the quiz for this article. that have led to energy-dense diets with reduced physical activity.<sup>1</sup> High-fat diets are often blamed for increased obesity rates; however, fats are diverse and respond differently in vivo.

Medium-chain triglycerides (MCTs) may counteract fat deposition in adipocytes by increasing thermogenesis and satiety.<sup>2</sup> The MCTs contain 8 to 12 carbon atoms and include caprylic acid (C8:0, octanoic acid), capric acid (C10:0, decanoic acid), and lauric acid (C12:0, dodecanoic acid). Foods high in MCTs include coconut oil (58%), palm kernel oil (54%), desiccated coconut (37%), and raw coconut meat (19%) (US Department of Agriculture National Nutrient Database). Average intakes of 1.35 g/day (0.7% of total energy intake) MCTs have been reported in the United States<sup>3</sup> and 0.2 g/day in Japan.<sup>4</sup> MCT is cleaved into glycerol and medium-chain fatty acids in the gut lumen.<sup>5</sup> The medium chain length

makes a smaller, more soluble molecule compared with a longchain fatty acid, giving it a preferential absorption and metabolic route in the body.<sup>6</sup> This physicochemical nature of medium-chain fatty acids allows them to pass into the portal vein on route to the liver to be rapidly metabolized via  $\beta$  oxidation with no requirement of reesterification in intestinal cells, incorporation into chylomicrons,<sup>7</sup> or the rate limiting enzyme carnitine acyltransferase for intramitochondrial transport.<sup>5</sup> In comparison, long-chain fatty acids have a slower route, being re-esterified in the small intestine and transported by chylomicrons via the lymphatic and vascular system before being oxidized for energy or stored.<sup>7</sup> Thus, rapid metabolism of MCTs reduces their opportunity of adipose tissue uptake.<sup>8</sup>

Studies in animals and human beings have shown increased energy expenditure and lipid oxidation with MCTs, specifically C8:0 and C10:0, compared with long-chain triglycerides (LCTs).<sup>5,9-16</sup> Increased satiety, resulting in reduced food intake, is another possible benefit from the fast oxidation of MCT through the formation of ketones,<sup>7</sup> although studies in humans have been inconsistent with some showing no effect,<sup>7,9,17,18</sup> whereas others showed increased satiety.<sup>19,20</sup> Replacement of MCT with LCT in the diet, therefore, has the potential to result in negative energy balance and weight loss over the long term.

Several human intervention studies have been conducted investigating the weight-reducing potential of MCT, with mixed results.<sup>21</sup> If weight loss attributes are confirmed for MCT, its incorporation into the diet could have important clinical application for healthy body weight management. MCTs may be included into the diet through the development of food products, such as oils, where proportions of LCT are replaced with MCT for commercial and domestic use or weight loss products (eg, meal replacements). The availability of modern fat technologies enables the production of food products containing higher amounts of MCT that are suitable for cooking and other purposes.

The association between dietary fats and low-density lipoprotein (LDL) cholesterol is well established<sup>22</sup>; therefore, it is important to consider the effects of MCT on blood lipid profiles to ensure no adverse effects. Results from intervention trials with MCT on lipid profiles have been inconsistent, with some reporting unfavorable changes<sup>23-25</sup> and others no change.<sup>24,25</sup>

The primary aim of our study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effects of MCT, specifically C8:0 and C10:0, to LCT on weight loss and body composition in healthy adults. Subgroup analyses were conducted to determine whether sex, baseline body weight status, length of intervention, or dosage affected the outcomes. The primary outcome measures were body mass, waist and hip circumference, total body fat, and subcutaneous and visceral fat. Secondary outcomes were blood lipids, including triglycerides (TG), total cholesterol, high-density lipoprotein (HDL) cholesterol, and LDL cholesterol.

# **METHODS**

### **Eligibility Criteria**

We reviewed RCTs, both parallel and crossover, published until March 2014 with no language restrictions. Only studies >3 weeks' duration were reviewed. All studies were peer reviewed and conference abstracts were excluded. In addition, the participants were required to be healthy and older than age 18 years. A body weight measurement was required at baseline and at the end point. Both ad libitum, weight maintaining, and reduced-calorie diets were included, but any exercise intervention studies were excluded. The interventions were to include C8:0 and C10:0 acids with the control containing a longer-chain fatty acid. A formal review protocol was not published.

### Literature Search

A systematic search was performed for all studies published before March 31, 2014, through several journal databases, including Web of Knowledge, Discover, PubMed, Scopus, New Zealand Science, and Cochrane CENTRAL. Reference lists of included trials were scanned for further relevant studies. A pilot literature search tested suitability of search words. The final search terms included *medium-chain fatty acid, mediumchain triglyceride*; *octanoic, decanoic, dodecanoic, caprylic, capric, or lauric; obesity, weight loss, overweight, body composition, or energy expenditure*; and *trial, intervention,* or *study.* Results from each database were downloaded into EndNote (version X4.0.2, 2010, Thomson Reuters). Duplicates were removed and abstracts were screened. Where an abstract met the eligibility requirements, the full article was read to ensure inclusion and exclusion criteria were met.

### Data Extraction and Quality Assessment

An extraction form was drafted to collect study details on authors; sources of funding; aim, objective, and hypothesis; study design and setting; population; intervention and delivery methods; possible confounders; outcomes; results; conclusions; and assessment of bias risk. The extraction table was piloted on one article independently by the authors and adapted to exclude any sources of discrepancies. Outcome results were collected in Excel (version 14.0.6129.5000, 2010, Microsoft Corp) for further calculation if required. Blood lipid results were converted, where necessary, to milligrams per deciliter from millimoles per liter using a conversion factor of 88.57 for TG and 38.6 for cholesterol.

A bias assessment was performed following the Cochrane risk of bias assessment<sup>26</sup> to assess the validity of studies. Selection, performance, detection, attrition, and reporting bias were reviewed and assessed at the study level. Crossover trials underwent a further assessment of bias risk to consider whether the effects of the first dietary intervention could be reversed during the washout period, whether any carryover effects could bias the second treatment period, whether the treatment order was randomized, and whether a paired statistical analysis was used.<sup>26</sup> In addition, commercial bias was identified where one or more of the authors were employees of the supplier of MCT trial products, there was a conflict of interest, and the control of data and publishing of results were not clearly stated.

Where a study had more than two arms, only relevant arms were selected for comparison and care was taken not to double count participants in the meta-analysis. Where a trial registration number was provided, the registry file was searched to determine reporting bias. Data for each study were extracted independently by one author and verified by the other. Any differences were resolved by discussion.


## **Statistical Analysis**

Data were analyzed using Review Manager (version 5.2.11, 2012, The Nordic Cochrane Centre, The Cochrane Collaboration). A fixed-effects model and inverse variance method was used to calculate the forest plot with a 95% CI. A random effects model was applied in subgroupings to minimize the risk of a false positive result.<sup>26</sup> The fixed-effect estimate gives the best estimate of the intervention effect, whereas the random-effect estimate gives an average intervention effect.<sup>26</sup>

For each outcome, the mean difference of change scores from baseline between intervention groups was used plus the standard deviation (SD). If the SD was not given, it was calculated from the standard error. If the SD or standard error was not available, it was imputed from the mean correlation coefficient for an outcome from other studies in the metaanalysis.<sup>26</sup> For outcomes using differing units of measure that could not be converted (eg, subcutaneous and visceral body fat were measured in kilograms and centimeters<sup>3</sup>), the standardized mean difference (SMD) was calculated. Heterogeneity between studies was calculated using the  $l^2$  statistic. Heterogeneity was identified when  $l^2 > 50\%$  or P < 0.10.<sup>26</sup> If heterogeneity was identified in any outcome, the reasons were explored or a random effects model was used.<sup>26</sup> If the heterogeneity could not be rectified, the meta-analysis for that particular outcome was not completed.

Where there were 10 or more studies for an outcome, publication bias was calculated using the Egger linear regression method.<sup>27</sup> Subgroup analysis was done a priori on study duration (<12 weeks or  $\geq$ 12 weeks), sex, and MCT intake (<8%, 8% to 16%, and >16% energy). It was not possible to do a subgroup analysis by baseline body weight status due to the overlapping of groups. Post hoc analysis was done on commercial- vs noncommercial-biased studies. Subgroup differences were assessed using  $\chi^2$  test. Sensitivity analysis was done on trials with a high bias (two or more high-risk assessment), trials with imputed data, crossover trials, and trials with high commercial bias. Results are shown as weighted mean difference or SMD with 95% CIs. Statistical significance was set at *P*<0.05.

# Identification



**Figure 1.** Preferred reporting items for systematic reviews and meta-analyses flow diagram for search of randomized controlled trials used in meta-analysis. Databases searched included Web of Knowledge, Discover, PubMed, Scopus, New Zealand Science, and Cochrane CENTRAL. Other sources of literature included reference lists of full-text articles included in meta-analyses.

Table. Characteristics of randomized controlled trials examining the effect of medium-chain triglycerides on weight, body composition, and blood lipid levels selected for this meta-analysis

	Methods and		C	Diet	
Study <sup>a</sup>	duration	Participants	Intervention	Control	Outcomes
Yost and Eckel DB <sup>b</sup> P <sup>c</sup> 4-12 wk 1989 <sup>34</sup>		16 obese women, aged 29-44 y in Colorado	800 kcal/d via formula containing 47% energy from CHO <sup>d</sup> , 22% energy from protein, 6% energy from LCT <sup>e</sup> and 24% energy from MCT <sup>f</sup> (~21 g/d)	800 kcal/d via formula containing 47% energy from CHO, 22% energy from protein, 31% energy from LCT (soy oil)	BW <sup>g</sup>
Temme and colleagues 1997 <sup>28</sup>	SB <sup>h</sup> P 6 wk	60 adults, BMI <sup>i</sup> 20-30, in the Netherlands	Margarine and foods, 10% energy from MCT (~24 g/d)	<ul> <li>i) Margarine and foods, 10% energy from myristic acid (C14:0)</li> <li>ii) Margarine and foods, 17% energy from oleic acid</li> </ul>	BW, TG <sup>j</sup> , total cholesterol, HDL <sup>k</sup> cholesterol, LDL <sup>I</sup> cholesterol
Feldheim 2001 <sup>36</sup>	$\begin{array}{l} \text{C-O}^{m} \\ \text{2}{\times}4 \text{ wk } + \\ \text{2 wk washout} \end{array}$	35 women, aged 19-24 y, normal BMI, in Prague	Fat provided, 5% energy from MCT (~12.5 g/d)	Unknown LCT	BW
Krotkiewski DB P 2001 <sup>19</sup> 4 wk		66 obese, perimenopausal women in Sweden	579 kcal/d via Adinax <sup>n</sup> powder; 13% energy from MCT (9 g/d), 21% energy from CHO, 20% energy from protein, mixed with nonfat milk (45% of energy)	579 kcal/d via Adinax powder; 13% energy from LCT, 21% energy from CHO, 20% energy from protein, mixed with nonfat milk (45% of energy)	BW, body fat, TG, total cholesterol
			3 liquid m	eals per day	
Matsuo and colleagues 2001 <sup>30,0</sup>	P 12 wk	13 men aged 18-20 y, normal BMI, in Japan	Liquid formula supplement, 20 g SMLCT <sup>p</sup> , <1% energy from MCT	Liquid formula supplement, 20 g soybean oil	BW, total adipose, TG, total cholesterol, HDL cholesterol, LDL cholesterol
2001				d libitum food	
Tsuji and colleagues 2001 <sup>33,0</sup>	DB P 12 wk	78 adults in Japan	Breakfast bread containing ~4% energy from MCT (10 g/d)	Breakfast bread containing 10 g/d LCT (70% rapeseed, 30% soybean oil)	BW, body composition, TG and total cholesterol
			dinners p 250 g	aged lunch, provided plus ¡ fruit and rables/day	
			veget	adies/ day	(continued on next page)

(continued on next page)

**Table.** Characteristics of randomized controlled trials examining the effect of medium-chain triglycerides on weight, body composition, and blood lipid levels selected for this meta-analysis (*continued*)

	Methods and		Die	et	
Study <sup>a</sup>	duration	Participants	Intervention	Control	Outcomes
	DB P 12 wk	82 adults, mean BMI=25, in Japan	Breakfast bread containing 14 g MLCT <sup>q</sup> , providing 1.7 g MCT, <1% energy	Breakfast bread containing 14 g LCT (70% rapeseed, 30% soybean oil)	BW, body composition, TG, total cholesterol, HDL cholesterol, and LDL cholesterol
			Pre-packaged I		
				us 250 g fruit tables/day	
Nosaka and colleagues 2003 <sup>31,0</sup>	DB P 12 wk	64 adults, mean BMI=25, in Japan	14 g margarine/d containing <2% energy from MCT (5 g/d)	14 g margarine/d containing LCT (70% rapeseed, 30% soybean oil) (5 g/d)	BW, body composition, TG, and total cholesterol
			Prepackaged I		
			provided plu		
			•	etables/d	
St Onge and colleagues 2003 <sup>10</sup> Bourque and colleagues	C-O 2×27 d, 4-8 wk washout	17 obese women, mean age 44 y, mean BMI=32, in Montreal	30% from fat mixture containing 20% energy from MCT (~54 g/d) plus 22 mg/kg/BW stanol/sterol mixture	30% energy from beef tallow	BW, body composition, TG, total cholesterol, HDL cholesterol, and LDL cholesterol
2003 <sup>38</sup>					
				at, 45% energy	
				nd 15% energy	
	<u> </u>	<b>25</b>		protein	
St Onge and colleagues 2003 <sup>9</sup>	C-O 2×4 wk, 4-wk washout	25 overweight men, mean age 43 y, in Montreal	30% energy from structured oil containing 20% energy from MCT plus 3% stanol/sterol mixtu	30% energy from olive oil re	BW, body composition, and blood lipid levels
St Onge and			3 isoenergeti		
colleagues 2003 <sup>39</sup>				at, 45% energy nd 15% energy	
St-Onge and				protein	
Jones 2003 <sup>40</sup>			nom		
					(continued on next page)

Table. Characteristics of randomized controlled trials examining the effect of medium-chain triglycerides on weight, body composition, and blood lipid levels selected for this meta-analysis (continued)

	Methods and		D	Diet	
Study <sup>a</sup>	duration	Participants	Intervention	Control	Outcomes
Roynette and colleagues 2008 <sup>35,0</sup> Rudkowska and	SB C-O 2×6 wk, 4-8 wk washout	32 hypercholesterolemic, overweight men, 18-45 y, in Montreal	30% energy from structured oil containing 13% energy from MCT (48 g/d) plus 6%-10% sterol esters	30% energy from olive oil	BW and body composition
colleagues 2006 <sup>41,0</sup>			energy fr	tic meals 40% rom fat, 45% om CHO, and ly from protein	
St Onge and Bosarge 2008 <sup>32</sup> St Onge and colleagues	DB P 16 wk	49 overweight adults, 19-50 y, in Birmingham, AL	12% energy from MCT, women: 18 g/d; men: 24 g/d Study muffi	12% energy from olive oil ns (10 g) and	BW, body composition, TG, total cholesterol, HDL cholesterol, LDL cholesterol
2008 <sup>42</sup>			•	oil (8-14 g)	
Xue 2009 <sup>29,0</sup> Xue 2009 <sup>43,0</sup> Liu 2009 <sup>37,0</sup> Zhang 2010 <sup>44,0</sup>	DB P 8 wk	101 adults, BMI >22, high triglycerides, China	25-30 g/d MLCT oil containing <2% energy from MCT, 3.25-3.9 g/d	25-30 g/d LCT oil	BW, body composition, TG, total cholesterol, HDL cholesterol, and LDL cholesterol

<sup>b</sup>DB: double-blind. <sup>c</sup>P=parallel. <sup>d</sup>CHO=carbohydrate. <sup>e</sup>LCT=long-chain triglycerides.

 $\sim$ 

 $^{a}$ Where >1 article is published for the study, the primary study is listed first.

<sup>f</sup>MCT=medium-chain triglycerides. <sup>g</sup>BW=body weight. <sup>h</sup>SB=single blind. <sup>i</sup>BMI=body mass index.

<sup>j</sup>TG=triglycerides. <sup>k</sup>HDL=high-density lipoprotein. LDL=low-density lipoprotein.

<sup>m</sup>C-O=crossover.

<sup>n</sup>Norovital.

<sup>o</sup>Risk of commercial bias, where authors are also employees of the company supplying the MCT and ownership of data and publishing is not declared.

<sup>P</sup>SMLCT=structured medium long-chain triglycerides.

<sup>q</sup>MLCT=medium long-chain triglycerides.

JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS

254






The literature search identified 701 possible studies, 675 were eliminated based on title and abstract because they did not meet the inclusion criteria (Figure 1). A full-text assessment was completed on 26 articles: 21 articles represented 13 RCTs that met the inclusion criteria and are described in the Table. The five excluded studies are referenced in Figure 1.

The final analysis included 239 and 250 individuals in the intervention or control diet, respectively, for nine parallel studies<sup>4,19,28-34</sup> and 90 participants in four crossover trials.<sup>9,10,35,36</sup> Eight studies provided information by sex: four crossover studies<sup>9,10,35,36</sup> with 42 women and 48 men, and four parallel studies<sup>19,29,30,37</sup> of 94 women and 80 men. Study length ranged from 27 days to 16 weeks, equating to 10 diet weeks/person. Body mass index ranged from 20 to >30. Intake of MCT ranged from <1% to 24% of energy intake. Body fat was assessed in nine studies using a variety of methods: air-displacement method,<sup>4,31,33</sup> bioelectrical impedance analyzer,<sup>29</sup> computed tomography,<sup>4,29,31-33</sup> dual-energy x-ray absorptiometry,<sup>19,32</sup> and magnetic resonance imaging.<sup>9,10,35</sup> Eleven RCTs measured blood lipid levels.<sup>4,9,10,19,28-33,35</sup> Differing controls were used but the primary controls were monounsaturated fatty acid and polyunsaturated fatty acid sources; for example, soybean oil, rapeseed oil, and olive oil containing 18 carbon atoms.<sup>4,9,28-35</sup> Two studies used saturated fatty acid sources, including myristic acid (C14:0)<sup>28</sup> and beef tallow (C15:0, C16:0),<sup>10</sup> and a further two studies described the control as an  $LCT^{19,36}$  (see the Table).

### **Quality Assessment of Studies**

No studies were excluded based on quality of study, although many studies did not report sufficient information for a clear bias assessment. The risk of bias for each study is summarized in Figure 2. A major possible source of bias was selection bias. Only one study detailed a method through random numbers<sup>29</sup>; other studies mentioned randomization, but no method was given. Allocation concealment was seen in two using central allocation<sup>29</sup> and opaque containers.<sup>32</sup> Performance bias had the best result: six studies had doubleblinding,<sup>4,19,29,31,33,34</sup> one study was single-blind,<sup>35</sup> and remaining studies did not discuss blinding<sup>9,10,30,36</sup> or there was a possibility the blinding could have been broken<sup>32</sup> or unclear.<sup>28</sup> Detection bias was eliminated in two studies<sup>29,32</sup> and not mentioned in 11 studies.<sup>4,9,10,19,28,30,31,33-36</sup> Attrition bias was low in three studies with no dropouts.<sup>19,30,34</sup> The remaining studies did a completers analysis and it is unlikely the results would substantially depart from original allocation.<sup>4,9,10,28,29,31-33,35,36</sup> Selective reporting bias was seen in two studies: one study failed to report subgroups of in- and outpatients with differing study durations<sup>34</sup>; another study did not report hip and waist circumference measurements taken and provided insufficient information for body weight to be included in the meta-analysis.<sup>30</sup> Low risk of reporting bias was seen in four studies where all expected outcomes were reported.<sup>4,29,31,32</sup> The remaining studies had unclear risk because some expected outcomes might not have been reported.<sup>9,10,19,28,33,35,36</sup> Commercial bias was found in six studies.<sup>4,29-31,33,35</sup>

The risks of bias from four crossover trials were assessed.<sup>9,10,35,36</sup> Study design was considered suitable for weight maintenance and the washout period was sufficient at



**Figure 2.** Risk of bias table showing judgments on each risk factor for each primary study included in meta-analysis. +=low risk (green). ?=unclear risk (yellow). -=high risk (red).

	r	ИСТ		Co	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean [kg]	SD [kg]	Total	Mean [kg]	SD [kg]	Total	Weight	IV, Fixed, 95% CI [kg]	Year	IV, Fixed, 95% CI [kg]
Yost & Eckel (34)	-9.7	3.39	8	-8.6	4.53	8	0.5%	-1.10 [-5.02, 2.82]	1989	· · · ·
Temme et al *(28)	0	2.09	10	0	2.57	19	2.7%	0.00 [-1.74, 1.74]	1997	
Temme et al ** <b>(28)</b>	0	2.09	11	0	2.22	20	3.3%	0.00 [-1.57, 1.57]	1997	
Krotkiewski (19)	-8.5	4.76	22	-8.1	5.02	22	1.0%	-0.40 [-3.29, 2.49]	2001	
Tsuji et al <b>#(33)</b>	-3.3	2.32	15	-3.08	1.85	7	2.5%	-0.22 [-2.02, 1.58]	2001	
Tsuji et al <b>##(33)</b>	-6.12	2.55	26	-4.78	2.19	30	5.2%	-1.34 [-2.59, -0.09]	2001	
Matsuo et al (30)	1.83	0	7	0.91	0	6		Not estimable	2001	
Feldheim (36)	-0.6	2.2	35	-1.1	2.2	35	7.7%	0.50 [-0.53, 1.53]	2001	
St-Onge et al (9)	-1.03	1.25	25	-0.62	1.45	25	14.5%	-0.41 [-1.16, 0.34]	2003	-•+
Nosaka et al (31)	-4.2	2.8	33	-2.9	2	31	5.8%	-1.30 [-2.49, -0.11]	2003	
St-Onge et al (10)	-0.87	0.66	17	-0.84	0.91	17	28.6%	-0.03 [-0.56, 0.50]	2003	+
Kasai et al <b>(4)</b>	-4.5	2.53	40	-3.3	2.59	42	6.7%	-1.20 [-2.31, -0.09]	2003	
Roynette et al (35)	-1.46	1.92	23	-1.17	1.92	23	6.6%	-0.29 [-1.40, 0.82]	2008	
St-Onge & Bosarge (32)	-3.16	1.96	16	-1.41	1.9	15	4.4%	-1.75 [-3.11, -0.39]	2008	——
Xue et al <b>(29)</b>	-2.1	2.6	51	-0.7	1.9	50	10.4%	-1.40 [-2.29, -0.51]	2009	
Total (95% CI)			339			350	100.0%	-0.51 [-0.80, -0.23]		•
Heterogeneity: Chi <sup>2</sup> = 19.8	87, df = 13 (P	= 0.10); l <sup>2</sup>	= 35%						_	
Test for overall effect: Z =	3.51 (P = 0.0	004)								-4 -2 0 2 4 Favors MCT Favors control

**Figure 3.** Meta-analysis for changes in body weight (in kilograms) in randomized control trials that compared dietary medium-chain triglycerides (MCTs) with a longer-chain triglyceride (control) shows a favorable effect of MCT intervention on body weight. \*Oleic acid as control. \*\*Myristic acid as control. \*Body mass index <23. ##Body mass index  $\geq$ 23. IV=inverse variance. SD=standard deviation. NOTE: Information from this figure is available online at www.andjrnl.org as part of a PowerPoint presentation.

4 or 8 weeks, although one study only had a 2-week washout.<sup>36</sup> The risk of a carryover effect was not clear, nor were data from the first period available. In two cases, the SD of the mean difference had to be imputed.<sup>10,36</sup>

All studies, except one,<sup>30</sup> had methods to check dietary compliance. Ten studies provided some or all food to participants.<sup>4,9,10,19,31-36</sup> One study monitored physical activity levels,<sup>31</sup> whereas eight studies advised participants to maintain current activity levels.<sup>4,9,10,28,29,33-35</sup> Four studies limited alcohol consumption.<sup>4,31,33,34</sup> Three studies were hypocaloric.<sup>19,32,34</sup> Three studies added phytosterols to the intervention oil<sup>9,10,35</sup> and one added psyllium.<sup>34</sup>

## Effect of MCTs on Body Composition in Adults

**Body Weight.** Twelve studies—eight parallel<sup>4,19,28,29,31-34</sup> and four crossover trials<sup>9,10,35,36</sup>—recorded body weight outcomes (Figure 3). The weighted mean difference for body weight significantly favored MCT with small effect (-0.51 kg [95% CI - 0.80 to -0.23 kg]). Moderate heterogeneity was seen in the meta-analysis for body weight ( $l^2=35\%$ ; P=0.10). There did not appear to be one study driving the moderate heterogeneity. Sensitivity analyses did not change this result except for study design where parallel vs crossover trials removed the significance for all the subgroup analyses, perhaps due to loss of statistical power. Furthermore, a post hoc sensitivity analysis of hypocaloric studies<sup>19,32,34</sup> did not alter the results. Subgroup analysis identified significant differences between duration, dose, and commercial biased groups. Studies  $\geq$ 12 weeks showed greater weight loss than those < 12 weeks (*P*=0.004). More weight was lost with doses <8% energy compared with doses >16% energy (*P*=0.03). More weight was lost in the commercially biased trials compared with the noncommercially biased trials (P=0.001).

**Waist and Hip Circumference.** Waist<sup>4,29,31-33</sup> and hip circumferences<sup>4,29,31</sup> were recorded in five and three parallel studies as shown in Figure 4. The weighted mean difference significantly favored MCT in waist circumference with medium effect (-1.46 cm [95% CI -2.04 to -0.87 cm]) and hip circumference with small effect (-0.79 cm [95% CI -1.27 to -0.30 cm]). Heterogeneity was not present for either waist ( $l^2$ =0%; *P*=0.71) or hip circumference ( $l^2$ =0%; *P*=0.87) (Figure 4). A subgroup analysis did not show any intergroup differences and results were not affected by a sensitivity analysis.

Total body, Subcutaneous, and Abdominal Visceral Fat. Nine studies—six parallel<sup>4,19,29,31-33</sup> and three crossover trials<sup>9,10,35</sup>—recorded outcomes for total body fat. Seven studies—four parallel<sup>4,29,31,33</sup> and three crossover trials<sup>9,10,35</sup>—measured outcomes for total subcutaneous fat. Six studies—five parallel studies<sup>4,29,31-33</sup> and one crossover trial<sup>35</sup>—recorded outcomes for visceral fat. Studies are detailed in Figure 5. The SMD significantly favored MCT in total body fat with small effect (SMD=–0.39 [95% CI –0.57 to –0.22]), total subcutaneous fat with medium effect (SMD=–0.46 [95% CI –0.64 to –0.27]) and visceral fat with medium effect (SMD=–0.55 [95% CI –0.75 to –0.34]). Heterogeneity was not present in total body fat ( $I^2$ =0%; P=0.62), total subcutaneous fat ( $I^2$ =20%; P=0.27), or visceral fat ( $I^2$ =0%; P=0.53). A subgroup analysis did not show any intergroup differences and results were not affected by a sensitivity analysis.

# Effect of MCTs on Blood Lipid Levels in Adults

Three crossover studies<sup>9,10,35</sup> included phytosterols in the intervention oil; they have been excluded from analysis of blood lipids because phytosterols may confound results.<sup>42</sup>

	1	ИСТ		Co	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean [cm]	SD [cm]	Total	Mean [cm]	SD [cm]	Total	Weight	IV, Fixed, 95% CI [cm]	Year	IV, Fixed, 95% CI [cm]
2.1.1 Waist circumference	e									
Tsuji et al <b>#(33)</b>	-3.71	2.71	15	-2.4	1.59	7	10.4%	-1.31 [-3.12, 0.50]	2001	
Tsuji et al ##(33)	-5.67	2.55	26	-3.74	2.74	30	17.7%	-1.93 [-3.32, -0.54]	2001	<b>-</b> _
Kasai et al (4)	-4	2.53	40	-2.8	2.59	42	27.7%	-1.20 [-2.31, -0.09]	2003	
Nosaka et al (31)	-5.1	3.1	33	-3.3	1.9	31	21.8%	-1.80 [-3.05, -0.55]	2003	
St-Onge & Bosarge (32)	-2.4	3.1	15	-2.5	2.99	14	6.9%	0.10 [-2.12, 2.32]	2008	
Xue et al (29)	-2.6	3.5	51	-0.9	4.1	50	15.4%	-1.70 [-3.19, -0.21]	2009	
Subtotal (95% CI)			180			174	100.0%	-1.46 [-2.04, -0.87]		•
Heterogeneity: Chi <sup>2</sup> = 2.97	, df = 5 (P = 0	0.71); I <sup>2</sup> = 0	1%							
Test for overall effect: Z =	4.90 (P < 0.0	0001)								
2.1.2 Hip circumference										
Kasai et al <b>(4)</b>	-2.9	1.9	40	-2	1.3	42	47.2%	-0.90 [-1.61, -0.19]	2003	
Nosaka et al (31)	-2.9	2.1	33	-2.3	1.5	31	29.9%	-0.60 [-1.49, 0.29]	2003	
Xue et al (29)	-1.5	2.5	51	-0.7	2.7	50	22.9%	-0.80 [-1.82, 0.22]	2009	
Subtotal (95% CI)			124			123	100.0%	-0.79 [-1.27, -0.30]		•
Heterogeneity: Chi <sup>2</sup> = 0.27	7, df = 2 (P = 0	0.87); I <sup>2</sup> = 0	1%							
Test for overall effect: Z =	3.17 (P = 0.0	02)								
									-	
										-4 -2 0 2 4 Favors MCT Favors control

**Figure 4.** Meta-analysis for changes in waist and hip circumference (in centimeters) in randomized control trials that compared dietary medium-chain triglycerides (MCTs) with a longer-chain triglycerides (control) shows a favorable effect of MCT intervention on waist and hip circumference. <sup>#</sup>Body mass index <23. <sup>##</sup>Body mass index  $\geq$ 23. IV=inverse variance. SD=standard deviation.

Similarly, baseline lipid levels may affect lipid responses to dietary interventions<sup>50</sup>; because the study by Xue and colleageus<sup>29</sup> was the only study conducted on patients with hypertriglyceridemia this study was excluded from the blood lipids analysis.

Seven parallel studies<sup>4,19,28,30-33</sup> recorded outcomes for TG with no heterogeneity ( $I^2=0\%$ ; P=0.77). MCTs did not affect TG (0.00 mg/dL; 95% CI -8.04 to 8.04 mg/dL [0.00 mmol/L; 95% CI -0.09 to 0.09 mmol/L]). Seven parallel<sup>4,19,28,30-33</sup> studies recorded outcomes for total cholesterol. MCT did not affect total cholesterol (-2.33 mg/dL; 95% CI -6.84 to 2.18 mg/dL [-0.06 mmol/L; 95% CI -0.18 to 0.06 mmol/L]) and no heterogeneity ( $l^2=0\%$ ; P=0.46) was present. Four parallel<sup>4,28,31,32</sup> studies recorded outcomes for LDL cholesterol with small heterogeneity ( $I^2$ =36%; P=0.18). MCT did not affect LDL cholesterol levels (-2.91 mg/dL; 95% CI -7.62 to 1.79 mg/dL [-0.08 mmol/L; 95% CI -0.20 to 0.05 mmol/L]). Five parallel studies<sup>4,28,30-32</sup> recorded outcomes for HDL cholesterol with no heterogeneity ( $I^2=0\%$ ; P=0.54). MCT did not affect HDL cholesterol levels (-1.35 mg/dL; 95% CI -3.02 to 0.31 mg/dL [-0.03 mmol/L: 95% CI -0.08 to 0.01 mmol/L]). Studies and results are summarized in Figure 6. Subgroup analyses did not show any intergroup differences and sensitivity analyses did not alter any results. Furthermore, a post hoc sensitivity analysis of studies using a saturated fatty acid as a control<sup>10,28</sup> did not alter the results.

### **Publication Bias**

In this meta-analysis, publication bias was not detected for weight loss outcomes, but there was a trend for publication bias in total body fat outcomes (P=0.05) (Figure 7).

## DISCUSSION

The findings from our meta-analysis suggest consuming MCTs as part of a diet compared with LCTs may result in a small average reduction in body weight of 0.51 kg (range=0.80 to 0.23 kg) over an average 10-week period. Waist and hip circumferences, total body fat, subcutaneous fat, and visceral fat were also significantly reduced and no changes were seen in TG, total cholesterol, LDL cholesterol, and HDL cholesterol when dietary MCT was compared with LCT. Although the reduction in body weight was small, it may be clinically relevant. When body weight is decreased by 1 kg, the associated risk of developing diabetes is reduced by 16%.<sup>51</sup> Nonetheless, several factors may have affected the quality of the meta-analysis results, which limits firm conclusions. The study designs in this meta-analysis were highly variable, including trials with very-low-calorie diets in obese women,<sup>19,34</sup> with normal-weight individuals,<sup>29,33</sup> or obese and overweight individuals where energy intake was highly controlled for weight maintenance<sup>4,9,10,33,35</sup> or on freefeeding weight-loss diets.<sup>32</sup> Dosages of MCT varied considerably from <1% percent energy (2 g/day) up to >20% energy (54 g/day) and duration of studies varied from 4 to 16 weeks. The reporting of studies was incomplete with few studies providing sufficient information to make a clear bias assessment. In addition, 6 out of 13 studies were identified with high risk of commercial bias.4,29-31,33,35

A recent systematic review of acute, short- and long-term studies published between 2000 and 2010 concluded that dietary intake of MCTs may be associated with improved body composition and increased energy expenditure without obvious effects on food intake.<sup>21</sup> The authors indicated that the results were inconclusive and further studies are

		МСТ		С	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI Year	IV, Fixed, 95% CI
3.1.1 Total body fat									
Krotkiewski (19)	-5.8	6.91	22	-4.9	6.04	22	8.7%	-0.14 [-0.73, 0.46] 2001	
Tsuji et al ##(33)	-4.57	2.55	26	-3.61	2.19	30	10.8%	-0.40 [-0.93, 0.13] 2001	+
Tsuji et al #(33)	-2.36	1.94	15	-2.49	1.32	7	3.8%	0.07 [-0.83, 0.97] 2001	
Kasai et al (4)	-4.4	2.53	40	-3.3	1.94	42	15.8%	-0.48 [-0.92, -0.05] 2003	
St-Onge et al (10)	-0.61	1.57	17	-0.54	1.98	17	6.7%	-0.04 [-0.71, 0.63] 2003	-+
St-Onge et al (9)	-0.83	1.23	24	-0.31	1.47	24	9.3%	-0.38 [-0.95, 0.19] 2003	+
Nosaka et al (31)	-3.8	2.4	33	-2.4	1.7	31	12.0%	-0.66 [-1.17, -0.16] 2003	
Roynette et al (35)	-1.17	4.96	20	-1.34	4.96	20	7.9%	0.03 [-0.59, 0.65] 2008	_ <b>_</b>
St-Onge & Bosarge (32)	-2.232	2.28	16	-0.694	2.28	15	5.8%	-0.66 [-1.38, 0.07] 2008	
(ue et al (29)	-1	2.3	51	0.2	1.8	50	19.2%	-0.58 [-0.97, -0.18] 2009	
Subtotal (95% CI)			264			258	100.0%	-0.39 [-0.57, -0.22]	•
leterogeneity: Chi <sup>2</sup> = 7.22	. df = 9 (	P = 0.61	);  ² = (	)%					
Test for overall effect: Z =									
3.1.2 Total subcutaneous	s fat								
Гsuji et al <b>#(33)</b>	-19.9	14.33	15	-26	11.11	7	4.4%	0.44 [-0.47, 1.34] 2001	
ſsuji et al ##(33)	-48.8	26.01	26	-32.6	2.74	30	11.8%	-0.90 [-1.45, -0.34] 2001	_ <b></b>
St-Onge et al (9)	-0.54	0.784	24	-0.17	0.93	24	11.0%	-0.42 [-1.00, 0.15] 2003	+
Kasai et al (4)	-36	26.56	40	-23.9	19.44	42	18.5%	-0.52 [-0.96, -0.08] 2003	
St-Onge et al (10)	-0.6	3.13	17	-0.5	3.24	17	8.0%	-0.03 [-0.70, 0.64] 2003	
losaka et al (31)	-38.2	29.9	33	-22.6	19.3	31	14.3%	-0.61 [-1.11, -0.11] 2003	
Roynette et al (35)	-1.77	3.38	20	-0.98	3.38	20	9.3%	-0.23 [-0.85, 0.39] 2008	
(ue et al (29)	-15.7	28.8	51	-3.1	19.6	50	22.9%	-0.51 [-0.90, -0.11] 2009	
Subtotal (95% CI)			226			221	100.0%	-0.46 [-0.64, -0.27]	•
Heterogeneity: Chi <sup>2</sup> = 8.70	, df = 7 (	P = 0.27	7); I <sup>2</sup> = 2	20%					
est for overall effect: Z =	4.70 (P <	< 0.0000	1)						
3.1.3 Visceral fat									
Гsuji et al <b>#(33)</b>	-16.4	10.07	15	-5.7	3.7	7	4.3%	-1.19 [-2.17, -0.21] 2001	
ſsuji et al ## <b>(33)</b>	-25.2	16.83	26	-22	15.34	30	14.8%	-0.20 [-0.72, 0.33] 2001	
Nosaka et al <b>(31)</b>	-12.2	11.2	33	-1.6	12.8	31	15.5%	-0.87 [-1.39, -0.36] 2003	
Kasai et al <b>(4)</b>	-15.9	12.65	40	-9.3	12.31	42	21.1%	-0.52 [-0.96, -0.08] 2003	
Roynette et al <b>(35)</b>	-0.3	0.52	20	-0.07	0.52	20	10.4%	-0.43 [-1.06, 0.19] 2008	
St-Onge & Bosarge (32)	-8.85	15.68	16	-1.32	15.68	14	7.7%	-0.47 [-1.20, 0.26] 2008	
Kue et al <b>(29)</b>	1	32.58	51	16.9	26.9	50	26.1%	-0.53 [-0.92, -0.13] 2009	
Subtotal (95% CI)			201			194	100.0%	-0.55 [-0.75, -0.34]	◆
Heterogeneity: Chi <sup>2</sup> = 5.08	, df = 6 (	P = 0.53	8); I² = 0	)%					
Test for overall effect: Z =	5.27 (P <	< 0.0000	)1)						
									-2 -1 0 1 2

**Figure 5.** Meta-analysis for changes in total body fat, total subcutaneous fat, and visceral fat (standard mean difference [Std Mean Difference]) in randomized control trials that compared dietary medium-chain triglycerides (MCTs) with a longer-chain triglycerides (control) shows a favorable effect of MCT intervention on body fat. <sup>#</sup>Body mass index <23. <sup>##</sup>Body mass index  $\geq$ 23. IV=inverse variance. SD=standard deviation.


warranted to determine adequate amounts and long-term side effects of MCTs. Our systematic review focused on chronic (>3 weeks) RCTs published until March 2014 comparing MCT with LCT on weight loss, body composition, and lipid profiles as secondary outcomes and included a meta-analysis of the outcomes. Although no new studies have been published since 2010, our review identified six RCTs<sup>28-31,34,36</sup> that were not included in the previous systematic review. Our systematic review furthermore provides a comprehensive critical appraisal of the current evidence and aims to identify gaps and areas of further research needed before recommendations for intake of MCTs to facilitate body weight management can be made.

All research is susceptible to bias, but industry-funded trials tend to report results favoring their own products<sup>52</sup> and possibly lead to publication bias. Industry funding is

	r	ИСТ		Co	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean [mg/dL]	SD [mg/dL]	Total	Mean [mg/dL]	SD [mg/dL]	Total	Weight	IV, Fixed, 95% CI [mg/dL] Y	ear	IV, Fixed, 95% CI [mg/dL]
4.1.1 Triglycerides										
Temme et al *(28)	9.73	25.66	10	5.31	23.01	19	18.0%	4.42 [-14.55, 23.39] 19	997	
Temme et al **(28)	9.73	25.66	11	-7.96	41.59	20	11.5%	17.69 [-6.02, 41.40] 19	997	
Krotkiewski (19)	-29.2	90.8	22	-21.24	85.21	22	2.4%	-7.96 [-59.99, 44.07] 20		
Tsuji et al #(33)	-44.25	63.19	26	-46.9	72.74	30	5.1%	2.65 [-32.95, 38.25] 20	001	
Matsuo et al (30)	13.72	33.45	7	9.91	31.86	6	5.1%		001	
Tsuji et al ##(33)	-24.78	58.23	15	-10.62	28.05	7			001	
Kasai et al (4)	-9.73	33.54	40	-4.42	40.18	42	25.3%		003	
Nosaka et al (31)	-11.06	37.35	33	-3.01	34.34	31	21.0%	-8.05 [-25.61, 9.51] 20		
St-Onge & Bosarge (32)	-6.19	43.1	16	-17.7	45.31	15	6.7%		008	
Subtotal (95% CI)			180			192	100.0%	0.00 [-8.04, 8.04]		◆
Heterogeneity: Chi <sup>2</sup> = 4.85	5. df = 8 (P = 0.77	);   <sup>2</sup> = 0%								
Test for overall effect: Z =										
4.1.2 Total cholesterol										
Temme et al *(28)	15.06	15.06	11	21.24	19.69	20	13.2%	-6.18 [-18.58, 6.22] 19	997	
Temme et al **(28)	15.06	15.06	10	6.18	15.06	19	15.3%	8.88 [-2.65, 20.41] 19	997	+
Tsuji et al #(33)	-21.62	19.42	15	-23.94	20.42	7	6.2%	2.32 [-15.72, 20.36] 20	001	
Krotkiewski (19)	-74.52	54.09	22	-70.27	49.58	22	2.2%	-4.25 [-34.91, 26.41] 20	001	
Tsuji et al ## <b>(33)</b>	-28.19	19.69	26	-30.12	27.49	30	13.2%	1.93 [-10.48, 14.34] 20	001	
Matsuo et al (30)	5.98	12.08	7	3.01	54.52	6	1.0%	2.97 [-41.56, 47.50] 20	001	
Nosaka et al (31)	-25.02	26.99	33	-13.01	24.02	31	13.0%	-12.01 [-24.51, 0.49] 20	003	
Kasai et al (4)	-32.05	21.97	40	-26.25	17.53	42	27.3%	-5.80 [-14.43, 2.83] 20	003	
St-Onge & Bosarge (32)	-11.58	23.05	16	-10.81	20.73	15	8.6%		800	
Subtotal (95% CI)			180			192	100.0%	-2.33 [-6.84, 2.18]		•
Heterogeneity: Chi <sup>2</sup> = 7.74	1, df = 8 (P = 0.46	i); l² = 0%								
Test for overall effect: Z =	1.01 (P = 0.31)									
4.1.3 LDL-C										
Temme et al *(28)	12.36	13.9	11	17.76	19.69	20	15.6%	-5.40 [-17.31, 6.51] 19	997	
Temme et al **(28)	12.36	13.9	10	3.47	13.9	19	19.6%	8.89 [-1.75, 19.53] 19	997	<b></b>
Kasai et al (4)	-27.03	21.97	40	-21.62	17.53	42	29.7%	-5.41 [-14.04, 3.22] 20	003	
Nosaka et al (31)	-19.5	22.51	33	-11.58	17.3	31	23.1%	-7.92 [-17.72, 1.88] 20	003	
St-Onge & Bosarge (32)	-13.13	18.76	16	-10.04	19.69	15	12.1%	-3.09 [-16.65, 10.47] 20	800	
Subtotal (95% CI)			110			127	100.0%	-2.91 [-7.62, 1.79]		◆
Heterogeneity: Chi <sup>2</sup> = 6.22	2, df = 4 (P = 0.18	s); I² = 36%								
Test for overall effect: Z =	1.21 (P = 0.23)									
4.1.4 HDL-C										
Temme et al *(28)	0.77	4.25	11	5.02	6.18	20	20.3%	-4.25 [-7.94, -0.56] 19	997	+
Temme et al **(28)	0.77	4.25	10	1.54	5.41	19			997	+
Matsuo et al (30)	0.81	7.53	7	0.62	8.07	6		0.19 [-8.34, 8.72] 20		_ <b>_</b>
Nosaka et al (31)	-1.7	7.99	33	0.39	6.91	31			003	
Kasai et al (4)	-1.93	7.34	40	-2.32	7.49	42		0.39 [-2.82, 3.60] 20		+
St-Onge & Bosarge (32)	2.32	8.8	16	2.32	9.46	15	6.7%		008	- <b>-</b>
Subtotal (95% CI)	2.02	0.0	117	2.52	0.10	133		-1.35 [-3.02, 0.31]		•
Heterogeneity: Chi <sup>2</sup> = 4.05	5, df = 5 (P = 0.54	); I <sup>2</sup> = 0%								
Test for overall effect: Z =										
	. ,									
										50 -25 0 25 50

**Figure 6.** Meta-analysis for changes in blood lipid levels (milligrams per deciliter<sup>a</sup>) in randomized control trials that compared dietary medium-chain triglycerides (MCT) with a longer chain triglyceride (control) shows no differences with MCT intervention. Four studies were excluded from the analysis: three contained phytosterols in the intervention oil and one had participants with hyperlipidemia. <sup>a</sup>To convert mg/dL triglycerides to mmol/L, multiply mg/dL by 0.0113. To convert mmol/L triglyceride to mg/dL, multiply mmol/L 88.6. Triglyceride of 159 mg/dL=1.80 mmol/L. To convert mg/dL cholesterol to mmol/L, multiply mg/dL by 0.0259. To convert mmol/L cholesterol to mg/dL, multiply mmol/L by 38.6. Cholesterol of 193 mg/dL=5.00 mmol/L. \*Oleic acid as control. \*\*Myristic acid as control. #Body mass index <23. ##Body mass index >23. IV=inverse variance. SD=standard deviation.

critical for the advancement of nutrition science and not all industry-funded trials are biased, particularly if parties follow the guiding principles for industry-funded research,<sup>53</sup> including (but not exhaustively) the conduct of transparent and objectively designed research according to accepted principles of scientific inquiry, the control of both study design and research remaining with the scientific investigators, freedom and obligation to publish the findings, and full disclosure of all financial interest. The six trials identified were cowritten by employees of the suppliers of the MCT trial products. As coauthors, it is assumed they contributed substantially to the design of the research; the



**Figure 7.** (A) Funnel plot of 12 randomized controlled trials (differentiated by funding) recording body weight outcomes when dietary medium-chain triglycerides were compared with a longer-chain triglyceride (control). An Egger linear regression analysis showed a symmetrical funnel plot (P=0.35). (B) Funnel plot of 10 randomized controlled trials recording total body fat outcomes when dietary medium-chain triglycerides were compared with a longer-chain triglyceride (control). An Egger linear regression analysis showed a trend toward an asymmetrical funnel plot (P=0.05).

acquisition, analysis, and interpretation of data; decision to publish and the drafting; revision; and approval of the final manuscript for submission, which may conflict with the guiding principles described above. Although these studies were generally well designed (randomized, controlled, blind, and sufficient duration), the reporting was poor resulting in unclear bias assessments for all, except Xue and colleagues.<sup>29</sup> It is interesting to note these studies were most likely to show a significant improvement in body weight despite being conducted on normal/overweight samples (four of five studies). They also provided the smallest doses,  $\leq 4\%$  energy from MCT, and were the longest in duration (four studies being 12 weeks' duration),<sup>4,30,31,33</sup> both factors shown in subgroup analysis to most favorably affect body weight.

The studies using the smallest doses<sup>4,29,31,33</sup> of <4% of energy (1.7 to 10 g/day), showed significant improvements in body weight ( $\sim$ -1.2 kg), body fat ( $\sim$ -1.0 kg), subcutaneous fat ( $\sim$ -10.3 cm<sup>2</sup>), and visceral fat ( $\sim$ -8.9 cm<sup>2</sup>) over 8 to 12 weeks compared with LCT and were conducted in Japanese<sup>4,31,33</sup> and Chinese<sup>29</sup> participants of normal weight. However, Tsuji and colleagues<sup>33</sup> only showed significant improvements in participants with body mass index >23. According to Kasai and colleagues,<sup>4</sup> 2 g/day MCT was small, yet 8 to 50 times the usual intake by Japanese people (0.2 g)day), and perhaps sufficient to accelerate lipid metabolism in human beings. Feldheim,<sup>36</sup> with young European women of normal body mass index, also used a small dosage of approximately 12.5 g/day (~5% energy) MCT in an ad libitum diet, but did not see significant changes in body weight. However, the energy and fat consumption were greater (P < 0.01 and P < 0.001) and protein consumption lower (P < 0.05) in the MCT group compared with the LCT group, which could have confounded the results.

In contrast. St Onge and colleagues showed that large doses of 20% energy from MCT ( $\sim$  54 g/day), as part of a strictly controlled weight maintenance diet in Canadian overweight men<sup>9</sup> and obese women,<sup>10</sup> resulted in increased energy expenditure and fat oxidation in both men and women, although weight loss was not significant compared with LCT. Similarly, Roynette and colleagues,<sup>35</sup> using the same study design as St Onge and colleagues<sup>9,10</sup> but a reduced dose (13% energy, 48 g/day), did not show significant differences in body weight and body composition between MCT and LCT in overweight men. The differences in weight loss between MCT and LCT in these trials may have been greater if the energy intake of the diets were not strictly controlled to maintain weight; instead, free feeding may allow the satiety effects of MCT to operate. The total fat intake in these studies were high at 40% energy compared with recommended intakes of 30% energy (US Department of Agriculture National Nutrient Database), which may have affected the outcomes. In addition, olive oil was used as control in two of these studies.<sup>9,35</sup> Olive oil consumption has been shown to increase fat oxidation<sup>54</sup> and lead to beneficial body composition changes<sup>55,56</sup> and could, therefore, have diminished the differences between MCT and control. St Onge and Bosarge<sup>32</sup> conducted a follow-up weight-loss trial in overweight men and women with a moderate amount of MCT (  $\sim 12\%$  energy: 18 g/day for women, 24 g/day for men). This dose was used by Dulloo and colleagues,<sup>11</sup> who showed 15 to 30 g/day significantly enhanced energy expenditure. St Onge and Bosarge<sup>32</sup> presented a decrease in body weight (-1.75 kg)[95% CI – 3.11 to –0.39 kg]) over 16 weeks compared with olive oil. In this trial, participants were allowed free feeding to capture the satiety effect of MCTs. However, the authors did not report dietary intake data to determine whether the energy intake was reduced in the MCT group. Temme and colleagues

conducted an ad libitum dietary study in the Netherlands on healthy adults (body mass index ranged from 20 to 30) with 10% energy from MCT (23.7 g/day) compared with either myristic acid margarine or sunflower oil margarine and failed to show weight loss effects in either trial arm, but the study's primary aim was to investigate the effects of MCT on lipid profiles.

Two studies<sup>19,34</sup> involving very-low-calorie diets (800 kcal/ day and 579 kcal/day) containing MCT doses of 24% energy (21 g/day) and 13% energy (9 g/day) in obese women were unable to show any effects on body weight and the results were highly variable with wide 95% Cls (Figure 3). Krotkiewski<sup>19</sup> showed greater reductions in body weight and body fat, a sparing effect on lean mass, and decreased hunger feelings that paralleled higher increases in ketone bodies with MCT compared with LCT after 2 weeks, but not after 4 weeks. They argued the effects of MCT might be transient, which is disputed by the results of our meta-analysis. The role of MCTs in very-low-calorie liquid diets; therefore, needs further investigation.

It is important to consider effects on lean mass and whether MCT could prevent or reduce the reduction in lean mass typically associated with weight-reducing diets. However, few studies have measured the effects of MCT on lean mass with inconsistent effects. St Onge and Bosarge<sup>32</sup> in their weight loss study showed lean mass was higher in the olive oil control group than in the MCT group at the end of the study ( $-0.93\pm0.41$  kg), whereas Krotkiewski<sup>19</sup> showed reduced loss of lean mass with MCT compared with LCT with their very-low-calorie diet.

With regard to the investigation of MCT on lipid profiles, it must be noted that blood lipid levels were a secondary outcome and not included as a search term; therefore, some key studies may have been omitted and firm conclusions cannot be drawn from this meta-analysis. This analysis has at least illustrated high doses of MCT do not adversely affect lipid profiles. This should be further investigated in a meta-analysis specifically designed to answer this research question.

One consistent quality from the studies is the method of dietary intervention. Many studies provided food to control energy and dietary fat intake, minimizing confounders and the risk of blinding being broken. Another strength of the trials included assessment of body composition to support body weight loss, although few studies measured lean mass. However, a limitation of the studies included the large variation of body mass index within studies and a failure to control for baseline body weight in many studies. In addition, the study of dietary MCT and weight loss has centered principally around two research groups: one in Japan<sup>4,30,31,33</sup> and the other from Canada<sup>9,10,35</sup>; thus, outcomes may not be applied to the general population. Subgroup analyses are observational only as they are not based on randomized comparisons,<sup>26</sup> so subgroup results should be used with caution. A limitation of this meta-analysis was that the retrieval, extraction, and bias analyses of the studies was conducted by one author and verified by the second author. However, the verification involved rigorous scrutiny of the information and it is unlikely to have affected the quality of the meta-analysis.

The replacement of LCT with MCT in the diet could potentially result in small decreases in body weight and composition without adversely affecting lipid profiles. However, several factors affected the quality of the metaanalysis results: inadequate reporting made it difficult to assess the quality of the trials; several studies were at high risk of commercial bias; and the study designs varied considerably with regard to dosage, duration, and control of energy intake. Further research is required by other independent research groups using large, robustly designed studies of sufficient duration (at least 12 weeks), with different MCT doses in different food matrixes, different populations, different body weight status groups (normal weight vs overweight/obese), sex, and age groups also capturing pre- and postmenopausal women. The effect of MCT on the fat:lean mass also needs to be investigated, particularly in weight loss studies and older adults. The longterm safety of MCT-enriched foods also need to be ascertained. Finally, all studies should be reported according to the Consolidated Standards of Reporting Trials guidelines (http:// www.consort-statement.org/), which provides a set of evidence-based recommendations for reporting randomized trials in a standard way that facilitates transparent and complete reporting that aids in their critical appraisal and interpretation.57

#### References

- World Health Organization. Obesity and overweight. Fact sheet No 311. 2013. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 25 July 2014.
- 2. Dulloo AG. The search for compounds that stimulate thermogenesis in obesity management: From pharmaceuticals to functional food ingredients. *Obes Rev.* 2011;12(10):866-883.
- **3.** US Department of Agriculture. *Nutrient Intakes From Food: Mean Amounts Counsumed per Individual, One Day, 2005-2006.* Washington, DC: US Department of Agriculture, Agricultural Research Service; 2008.
- Kasai M, Nosaka N, Maki H, et al. Effect of dietary medium- and longchain triacylglycerols (MLCT) on accumulation of body fat in healthy humans. Asia Pac J Clin Nutr. 2003;12(2):151-160.
- Bach AC, Babayan VK. Medium-chain triglycerides: An update. Am J Clin Nutr. 1982;36(5):950-962.
- 6. DeLany JP, Windhauser MM, Champagne CM, Bray GA. Differential oxidation of individual dietary fatty acids in humans. *Am J Clin Nutr.* 2000;72(4):905-911.
- Poppitt SD, Strik CM, MacGibbon AKH, McArdle BH, Budgett SC, McGill AT. Fatty acid chain length, postprandial satiety and food intake in lean men. *Physiol Behav.* 2010;101(1):161-167.
- Babayan VK. Medium chain triglycerides and structured lipids. *Lipids*. 1987;22(6):417-420.
- **9.** St Onge MP, Ross R, Parsons WD, Jones PJH. Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. *Obes Res.* 2003;11(3):395-402.
- **10.** St Onge MP, Bourque C, Jones PJH, Ross R, Parsons WE. Mediumversus long-chain triglycerides for 27 days increases fat oxidation and energy expenditure without resulting in changes in body composition in overweight women. *Int J Obes*. 2003;27(1):95-102.
- Dulloo AG, Fathi M, Mensi N, Girardier L. Twenty-four-hour energy expenditure and urinary catecholamines of humans consuming lowto-moderate amounts of medium-chain triglycerides: A doseresponse study in a human respiratory chamber. *Eur J Clin Nutr.* 1996;50(3):152-158.
- Scalfi L, Coltorti A, Contaldo F. Postprandial thermogenesis in lean and obese subject after meals supplemented with medium-chain and long-chain triglycerides. *Am J Clin Nutr.* 1991;53(5):1130-1133.
- **13.** Seaton TB, Welle SL, Warenko MK, Campbell RG. Thermal effect of medium-chain and long-chain triglycerides in man. *Am J Clin Nutr.* 1986;44(5):630-634.
- 14. Baba N, Bracco EF, Hashim SA. Enhanced thermogenesis and diminished deposition of fat in response to overfeeding with diet

containing medium chain triglyceride. Am J Clin Nutr. 1982;35(4): 678-682.

- Crozier G, Boisjoyeux B, Chanez M, Girard J, Peret J. Metabolic effects induced by long-term feeding of medium-chain triglycerides in the rat. *Metabolism*. 1987;36(8):807-814.
- Ferreira L, Lisenko K, Barros B, Zangeronimo M, Pereira L, Sousa R. Influence of medium-chain triglycerides on consumption and weight gain in rats: A systematic review. *J Anim Physiol Anim Nutr (Berl)*. 2014;98(1):1-8.
- Bendixen H, Flint A, Raben A, et al. Effect of 3 modified fats and a conventional fat on appetite, energy intake, energy expenditure, and substrate oxidation in healthy men. *Am J Clin Nutr.* 2002;75(1): 47-56.
- **18.** Clegg ME, Golsorkhi M, Henry CJ. Combined medium-chain triglyceride and chilli feeding increases diet-induced thermogenesis in normal-weight humans. *Eur J Nutr.* 2013;52(6):1579-1585.
- **19.** Krotkiewski M. Value of VLCD supplementation with medium chain triglycerides. *Int J Obes.* 2001;25(9):1393-1400.
- **20.** Van Wymelbeke V, Himaya A, Louis-Sylvestre J, Fantino M. Influence of medium-chain and long-chain triacylglycerols on the control of food intake in men. *Am J Clin Nutr.* 1998;68(2):226-234.
- 21. Rego Costa AC, Rosado EL, Soares-Mota M. Influence of the dietary intake of medium chain triglycerides on body composition, energy expenditure and satiety: A systematic review. *Nutr Hosp.* 2012;27(1):103-108.
- **22.** Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: Where does the evidence stand in 2010? *Am J Clin Nutr.* 2011;93(4): 684-688.
- **23.** Cater NB, Heller HJ, Denke MA. Comparison of the effects of mediumchain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans. *Am J Clin Nutr.* 1997;65(1):41-45.
- 24. Hill JO, Peters JC, Swift LL, et al. Changes in blood-lipids during 6 days of overfeeding with medium or long-chain triglycerides. *J Lipid Res.* 1990;31(3):407-416.
- **25.** Swift LL, Hill JO, Peters JC, Greene HL. Plasma-lipids and lipoproteins during 6 D of maintenance feeding with long-chain, medium-chain and mixed-chain triglycerides. *Am J Clin Nutr.* 1992;56(5):881-886.
- Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Oxford, England: The Cochrane Collaboration; 2011.
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Int Ed)*. 1997;315(7109): 629-634.
- 28. Temme EHM, Mensink RP, Hornstra G. Effects of medium chain fatty acids (MCFA), myristic acid, and oleic acid on serum lipoproteins in healthy subjects. *J Lipid Res.* 1997;38(9):1746-1754.
- **29.** Xue C, Liu Y, Wang J, et al. Consumption of medium- and long-chain triacylglycerols decreases body fat and blood triglyceride in Chinese hypertriglyceridemic subjects. *Eur J Clin Nutr.* 2009;63(7):879-886.
- **30.** Matsuo T, Matsuo M, Kasai M, Takeuchi H. Effects of a liquid diet supplement containing structured medium- and long-chain triacylglycerols on bodyfat accumulation in healthy young subjects. *Asia Pac J Clin Nutr.* 2001;10(1):46-50.
- **31.** Nosaka N, Maki H, Suzuki Y, et al. Effects of margarine containing medium-chain triacylglycerols on body fat reduction in humans. *J Atheroscl Thromb.* 2003;10(5):290-298.
- **32.** St Onge MP, Bosarge A. Weight-loss diet that includes consumption of medium-chain triacylglycerol oil leads to a greater rate of weight and fat mass loss than does olive oil. *Am J Clin Nutr.* 2008;87(3): 621-626.
- 33. Tsuji H, Kasai M, Takeuchi H, Nakamura M, Okazaki M, Kondo K. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women. J Nutr. 2001;131(11):2853-2859.
- **34.** Yost TJ, Eckel RH. Hypocaloric feeding in obese women metabolic effects of medium-chain triglyceride substitution. *Am J Clin Nutr.* 1989;49(2):326-330.
- Roynette CE, Rudkowska W, Nakhasi DK, Jones PJH. Structured medium and long chain triglycerides show short-term increases in fat oxidation, but no changes in adiposity in men. *Nutr Metab Cardiovasc Dis.* 2008;18(4):298-305.

- **36.** Feldheim W. Medium-chain triglycerides (MCT) and the control of body weight. Results of a clinical study performed in Prague. *Vita-MinSpur.* 2001;16(4):179-182.
- **37.** Liu YH, Wang J, Zhang RX, et al. A good response to oil with mediumand long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects. *Asia Pac J Clin Nutr.* 2009;18(3): 351-358.
- Bourque C, St Onge MP, Papamandjaris AA, Cohn JS, Jones PJH. Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and n-3 fatty acids improves cardiovascular risk profile in overweight women. *Metabolism*. 2003;52(6):771-777.
- **39.** St Onge MP, Lamarche B, Mauger JF, Jones PJH. Consumption of a functional oil rich in phytosterols and medium-chain triglyceride oil improves plasma lipid profiles in men. *J Nutr.* 2003;133(6): 1815-1820.
- 40. St Onge MP, Jones PJH. Greater rise in fat oxidation with medium-chain triglyceride consumption relative to long-chain triglyceride is associated with lower initial body weight and greater loss of subcutaneous adipose tissue. Int J Obes. 2003;27(12):1565-1571.
- **41.** Rudkowska I, Roynette CE, Nakhasi DK, Jones PJH. Phytosterols mixed with medium-chain triglycerides and high-oleic canola oil decrease plasma lipids in overweight men. *Metabolism*. 2006;55(3): 391-395.
- 42. St Onge MP, Bosarge A, Goree LLT, Darnell B. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J Am Coll Nutr. 2008;27(5):547-552.
- **43.** Xue C, Liu YH, Wang J, et al. Chinese hypertriglycerideamic subjects of different ages responded differently to consuming oil with medium- and long-chain fatty acids. *Biosci Biotechnol Biochem*. 2009;73(8):1711-1717.
- **44.** Zhang Y, Liu Y, Wang J, et al. Medium- and long-chain triacylglycerols reduce body fat and blood triacylglycerols in hypertriacylglycerolemic, overweight but not obese, Chinese individuals. *Lipids.* 2010;45(6):501-510.
- 45. Hainer V, Kunesova M, Stich V, Zak A, Parizkova J. The role of oils containing triacylglycerols and medium-chain fatty acids in the dietary treatment of obesity. The effect on resting energy expenditure and serum lipids. *Cas Lek Ceskh*. 1994;133(12):373-375.
- **46.** Han JR, Deng B, Sun J, et al. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. *Metabolism*. 2007;56(7):985-991.
- **47.** Assuncao ML, Ferreira HS, dos Santos AF, Cabral CR Jr, Florencio TMMT. Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity. *Lipids*. 2009;44(7):593-601.
- **48.** Siener R, Ehrhardt C, Bitterlich N, Metzner C. Effect of a fat spread enriched with medium-chain triacylglycerols and a special fatty acid-micronutrient combination on cardiometabolic risk factors in overweight patients with diabetes. *Nutr Metab.* 2011;8(21).
- **49.** Radonjic M, van Erk MJ, Pasman WJ, Wortelboer HM, Hendriks HFJ, van Ommen B. Effect of body fat distribution on the transcription response to dietary fat interventions. *Genes Nutr.* 2009;4(2):143-149.
- Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review. *Atherosclerosis*. 2006;189(1): 19-30.
- **51.** Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes Care*. 2006;29(9): 2102-2107.
- 52. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in clinicaltrials.gov. *Ann Intern Med.* 2010;153(3). 158-U148.
- Rowe S, Alexander N, Clydesdale FM, et al. Funding food science and nutrition research: Financial conflicts and scientific integrity. *Am J Clin Nutr.* 2009;89(5):1285-1291.
- 54. Piers LS, Walker KZ, Stoney RM, Soares MJ, O'Dea K. The influence of the type of dietary fat on postprandial fat oxidation rates: monounsaturated (olive oil) vs saturated fat (cream). *Int J Obes*. 2002;26(6):814-821.
- 55. Piers LS, O'Dea K, Walker KZ, Stoney RM, Soares MJ. Substitution of saturated with monounsaturated fat in a 4-week diet affects body

weight and composition of overweight and obese men. Br J Nutr. 2003;90(3):717-727.

**56.** Paniagua JA, de la Sacristana AG, Romero I, et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich

diet in insulin-resistant subjects. *Diabetes Care*. 2007;30(7): 1717-1723.

57. Schulz KF, Altman DG, Moher D, Grp C. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. *PLOS Med.* 2010;7(3).

### **AUTHOR INFORMATION**

K. Mumme is a student, Institute of Food, Nutrition, and Human Health, Massey University, Auckland, New Zealand, and The Liggins Institute, The University of Auckland, Auckland, New Zealand. W. Stonehouse is a senior research scientist, Institute of Food, Nutrition, and Human Health, Massey University, Auckland, New Zealand, and CSIRO, Food and Nutrition Flagship, Adelaide, South Australia, Australia.

Address correspondence to: Welma Stonehouse, PhD, CSIRO Food and Nutrition Flagship, PO Box 10041, Adelaide BC, South Australia, Australia 5000. E-mail: welma.stonehouse@csiro.au

#### STATEMENT OF POTENTIAL CONFLICT OF INTEREST

No potential conflict of interest was reported by the authors.

#### **FUNDING/SUPPORT**

None to report.

### ACKNOWLEDGEMENTS

The authors thank Florian Pichlmuller for his assistance in translating reference 36 into English.